Open AccessWeekly Carboplatin and Paclitaxel for Ovarian Cancer: The “Finer Points”
Author(s) -
Muggia Franco
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13572
Subject(s) - carboplatin , paclitaxel , ovarian cancer , schedule , oncology , medicine , chemotherapy , cisplatin , cancer , computer science , operating system
First‐line ovarian cancer platinum doublet is paclitaxel‐carboplatin. Superiority of weekly paclitaxel schedules has not been confirmed; however, a novel schedule with both drugs given weekly (days 1, 8, 15) followed by a 2‐week break may be advantageous to some.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom